Ruud Delwel

20.8k citations

163 papers · 9.1k indexed · 2 hit papers · h-index 50

Molecular Biology top 1%
Hematology top 0.05%
Immunology top 2%
Genetics top 0.5%
Cancer Research top 1%

Co-authors: Bob Löwenberg Peter J.M. Valk Claudia Erpelinck-Verschueren Bas J. Wouters H. Berna Beverloo Roel G.W. Verhaak Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Peter J. van der Spek
Topics: Acute Myeloid Leukemia Research (101 papers)Epigenetics and DNA Methylation (28 papers)Protein Degradation and Inhibitors (22 papers)
Cited by: Hematology Genetics Molecular Biology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences Nucleic Acids Research
Partner nations: Netherlands United States Germany

In The Last Decade

Ruud Delwel

160 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

2004 997 citations Peter J.M. Valk, Roel G.W. Verhaak et al. profile →
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

2010 578 citations María E. Figueroa, Claudia Erpelinck-Verschueren et al. Cancer Cell profile →

Peers

Countries citing papers authored by Ruud Delwel

Since Specialization

Citations

This map shows the geographic impact of Ruud Delwel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruud Delwel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruud Delwel more than expected).

Fields of papers citing papers by Ruud Delwel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruud Delwel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruud Delwel. The network helps show where Ruud Delwel may publish in the future.

Co-authorship network of co-authors of Ruud Delwel

This figure shows the co-authorship network connecting the top 25 collaborators of Ruud Delwel. A scholar is included among the top collaborators of Ruud Delwel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruud Delwel. Ruud Delwel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling 2024 ·Leukemia ·Mahesh Hegde,(unknown),Roger Mulet‐Lazaro,Mayumi Sugita,(unknown),Kai Hu,Claudia Gebhard,Mónica L. Guzmán,John H. Bushweller,Lihua Julie Zhu,Michael A. Brehm,Scot A. Wolfe,Ruud Delwel,Lucio H. Castilla	2
2	EVI1 drives leukemogenesis through aberrant ERG activation 2022 ·Blood ·Johannes Schmoellerl,Inês Amorim Monteiro Barbosa,Martina Minnich,(unknown),Leonie Smeenk,Marije Havermans,Thomas Eder,Tobias Neumann,Julian Jude,Michaela Fellner,Anja Ebert,(unknown),Ruud Delwel,Florian Grebien,Johannes Zuber	19
3	Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia 2021 ·Cancer Discovery ·Leonie Smeenk,(unknown),Roger Mulet‐Lazaro,Anja Ebert,Marije Havermans,(unknown),Michaela Fellner,(unknown),(unknown),Claudia Erpelinck-Verschueren,Tim Grob,Remco M. Hoogenboezem,François G. Kavelaars,Daniel R. Matson,(unknown),Eric M. Bindels,Alex Kentsis,Johannes Zuber,Ruud Delwel	29
4	Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML 2021 ·Blood ·Roger Mulet‐Lazaro,(unknown),Claudia Erpelinck-Verschueren,Eric M. Bindels,Mathijs A. Sanders,Carlo Vermeulen,Ivo Renkens,Peter J.M. Valk,Ari Melnick,Jeroen de Ridder,Michael Rehli,Claudia Gebhard,Ruud Delwel,Bas J. Wouters	13
5	The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops 2021 ·Nature Communications ·(unknown),Roger Mulet‐Lazaro,Claudia Erpelinck-Verschueren,(unknown),Marije Havermans,(unknown),(unknown),H. Berna Beverloo,Stefan Gröschel,Torsten Haferlach,Claudia Haferlach,Bas J. Wouters,Eric M. Bindels,Leonie Smeenk,Ruud Delwel	40
6	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML 2020 ·Cancer Discovery ·Sheng Li,(unknown),Jiahui Wang,Cem Meydan,Jacob L. Glass,Alan H. Shih,Ruud Delwel,Ross L. Levine,Christopher E. Mason,Ari Melnick	24
7	The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia 2018 ·Nature Communications ·Akihiko Numata,Hui Si Kwok,Akira Kawasaki,Jia Li,Qiling Zhou,Jon Kerry,Touati Benoukraf,Deepak Bararia,Feng Li,Erica Ballabio,Marta Tapia,Aniruddha J. Deshpande,Robert S. Welner,Ruud Delwel,Henry Yang,Thomas A. Milne,Reshma Taneja,Daniel G. Tenen	21
8	DNMT3A Haploinsufficiency Transforms FLT3 ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia 2016 ·Cancer Discovery ·Sara E. Meyer,Tingting Qin,David E. Muench,(unknown),Meenakshi Venkatasubramanian,(unknown),(unknown),Steven D. Gore,Ruud Delwel,Elisabeth Paietta,Martin S. Tallman,Hugo F. Fernández,Ari Melnick,Michelle M. Le Beau,Scott C. Kogan,Nathan Salomonis,María E. Figueroa,H. Leighton Grimes	70
9	Congenital thrombocytopenia in a neonate with an interstitial microdeletion of 3q26.2q26.31 2015 ·American Journal of Medical Genetics Part A ·Arjan Bouman,(unknown),Stefan Gröschel,Claudia Erpelinck-Verschueren,Mathijs A. Sanders,Ruud Delwel,Taco W. Kuijpers,Jan Maarten Cobben	13
10	Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias 2011 ·Cancer Research ·Brynn T. Kvinlaug,(unknown),Lars Bullinger,Mukundhan Ramaswami,Christopher Sears,(unknown),Stanley E. Lazic,Rachel Okabe,Axel Benner,Benjamin H. Lee,(unknown),Peter J.M. Valk,Ruud Delwel,Scott A. Armstrong,Hartmut Döhner,D. Gary Gilliland,Brian J.P. Huntly	37
11	Functional Crosstalk between Bmi1 and MLL/Hoxa9 Axis in Establishment of Normal Hematopoietic and Leukemic Stem Cells 2011 ·Cell stem cell ·Lan‐Lan Smith,Jenny Yeung,Bernd B. Zeisig,М. М. Попов,Ivo J. Huijbers,Josephine L. Barnes,Amanda Wilson,Erdogan Taskesen,Ruud Delwel,Jesús Gil,Maarten van Lohuizen,Chi Wai Eric So	89
12	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity 2010 ·Blood ·Erdogan Taskesen,Lars Bullinger,Andrea Corbacioglu,Mathijs A. Sanders,Claudia Erpelinck-Verschueren,Bas J. Wouters,(unknown),Frédérik Damm,Jürgen Krauter,Arnold Ganser,Richard F. Schlenk,Bob Löwenberg,Ruud Delwel,Hartmut Döhner,Peter J.M. Valk,Konstanze Döhner	262
13	Significance of Murine Retroviral Mutagenesis for Identification of Disease Genes in Human Acute Myeloid Leukemia 2006 ·Cancer Research ·Stefan J. Erkeland,Roel G.W. Verhaak,Peter J.M. Valk,Ruud Delwel,Bob Löwenberg,Ivo P. Touw	19
14	Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia 2006 ·Cancer Cell ·Karen Keeshan,Yiping He,Bas J. Wouters,Olga Shestova,Lanwei Xu,Hong Sai,Carlos G. Rodríguez,Ivan Maillard,John W. Tobias,Peter J.M. Valk,Martin Carroll,Jon C. Aster,Ruud Delwel,Warren S. Pear	195
15	Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status 2004 ·The Journal of Immunology ·(unknown),King H. Lam,Jon D. Laman,Peter J. Simons,Bob Löwenberg,Pieter Sonneveld,Ruud Delwel	42
16	Low expression of MDS1-EVI1–like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia 2003 ·Experimental Hematology ·Sahar Barjesteh van Waalwijk van Doorn-Khosrovani,Claudia Erpelinck-Verschueren,Bob Löwenberg,Ruud Delwel	14
17	Leukemic predisposition of pSca-1/Cb2 transgenic mice 2002 ·Experimental Hematology ·Marieke Joosten,Peter J.M. Valk,Meritxell Alberich-Jordà,(unknown),(unknown),(unknown),(unknown),Bob Löwenberg,Ruud Delwel	26
18	Treosulfan as an alternative conditioning agent in bone marrow transplantation. 1999 ·Blood ·RE Ploemacher,(unknown),JD Down,Joachim Baumgart,G R Westerhof,Ruud Delwel	12
19	The Peripheral Cannabinoid Receptor, Cb2, in Retrovirally-Induced Leukemic Transformation and Normal Hematopoiesis 1998 ·Leukemia & lymphoma ·Peter J.M. Valk,Ruud Delwel	22
20	Four of the Seven Zinc Fingers of the Evi-1 Myeloid-Transforming Gene Are Required for Sequence-Specific Binding to GA(C/T)AAGA(T/C)AAGATAA 1993 ·Molecular and Cellular Biology ·Ruud Delwel,T. Funabiki,Brent L. Kreider,Kazuhiro Morishita,James N. Ihle	106

About Ruud Delwel

Ruud Delwel is a scholar working on Hematology, Genetics and Immunology, having authored 163 papers that have together received 9.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (101 papers), Epigenetics and DNA Methylation (28 papers) and Protein Degradation and Inhibitors (22 papers). The work is most often cited by research in Hematology (5.3k citations), Genetics (1.4k citations) and Molecular Biology (5.4k citations). Ruud Delwel has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Bob Löwenberg, Peter J.M. Valk, Claudia Erpelinck-Verschueren, Bas J. Wouters, H. Berna Beverloo, Roel G.W. Verhaak, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Peter J. van der Spek, Michael Moorhouse and Wim L.J. van Putten. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact